SCHEMBL6018945

SCHEMBL6018945

CS(=O)(=O)OCCCCOC1CCC(CNCC(=O)Oc2ccc(Cl)cc2)CC1

nearest known ligand 0.38

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.38
KMT2A Q03164 3/20 0.37
MEN1 O00255 2/20 0.37
PKM P14618 1/20 0.36
ATF4 P18848 3/20 0.35
LMNA P02545 2/20 0.35
THRB P10828 1/20 0.34
TSHR P16473 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33
ADRB2 P07550 1/20 0.33
ADRB1 P08588 1/20 0.33
NR3C2 P08235 1/20 0.33
DPP4 P27487 1/20 0.32
HRH3 Q9Y5N1 2/20 0.32
TRPV1 Q8NER1 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6018447 0.81 ALDH1A1 (0.41) ALDH1A1KMT2AMEN1PKMLMNA
SCHEMBL6018951 0.80 LSS (0.41) ATF4LMNASMN1; SMN2
SCHEMBL6018955 0.80 LSS (0.41) ATF4LMNASMN1; SMN2
SCHEMBL7207244 0.79 LSS (0.41) KMT2AATF4DPP4HRH3
SCHEMBL7203539 0.78 LSS (0.38) ALDH1A1KMT2APKMATF4NR3C2
SCHEMBL5166328 0.73 VCP (0.46) ALDH1A1KMT2AMEN1ATF4NPC1
SCHEMBL5024143 0.73 VCP (0.46) ALDH1A1KMT2AMEN1ATF4NPC1
SCHEMBL6018451 0.71 LMNA (0.41) ALDH1A1PKMLMNAADRB2
SCHEMBL6018986 0.71 LMNA (0.41) ALDH1A1PKMLMNAADRB2
SCHEMBL6018455 0.71 LMNA (0.41) ALDH1A1PKMLMNAADRB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1456171-B1 SUBSTITUTED CYCLOHEXANE DERIVATIVES HOFFMANN LA ROCHE (CH) 2006-12-20 EP disclosed
US-20050272774-A1 Substituted cyclohexane derivatives ACKERMANN JEAN 2005-12-08 US disclosed
US-6953806-B2 Substituted cyclohexane derivatives HOFFMANN-LA ROCHE INC. (US) 2005-10-11 US disclosed
EP-1456171-A1 SUBSTITUTED CYCLOHEXANE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2004-09-15 EP disclosed
US-20030199550-A1 Substituted cyclohexane derivatives F.HOFFMANN-LA ROCHE AG (CH) 2003-10-23 US disclosed
WO-2003053919-A1 SUBSTITUTED CYCLOHEXANE DERIVATIVES F. HOFFMANN-LA-ROCHE AG (CH) 2003-07-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050272774-A1 Substituted cyclohexane derivatives LSS, CYP51A1, CYP8B1 ALDH1A1 629/4885KMT2A 3669/4885MEN1 1351/4885
US-20030199550-A1 Substituted cyclohexane derivatives CYP51A1, LSS, CYP46A1 ALDH1A1 498/4885KMT2A 3436/4885MEN1 1767/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.